Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 19/20 | 0.89 |
| ▸ | THRA | P10827 | 19/20 | 0.89 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.89 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.89 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.89 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.89 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13907340 | 0.94 | THRB (1.00) | THRBTHRACYP2C9UGT1A1ABCG2 | |
| SCHEMBL22632456 | 0.90 | THRB (0.91) | THRBTHRACYP2C9UGT1A1ABCG2 | |
| SCHEMBL29414827 | 0.90 | THRB (0.91) | THRBTHRACYP2C9UGT1A1ABCG2 | |
| SCHEMBL22643857 | 0.89 | THRB (0.87) | THRBTHRACYP2C9UGT1A1ABCG2 | |
| SCHEMBL22643856 | 0.89 | THRB (0.87) | THRBTHRACYP2C9UGT1A1ABCG2 | |
| SCHEMBL22632753 | 0.89 | THRB (0.87) | THRBTHRACYP2C9UGT1A1ABCG2 | |
| SCHEMBL31643418 | 0.89 | THRB (0.79) | THRBTHRACYP2C9UGT1A1ABCG2 | |
| SCHEMBL29414765 | 0.88 | THRB (0.87) | THRBTHRACYP2C9UGT1A1ABCG2 | |
| SCHEMBL22632499 | 0.88 | THRB (0.87) | THRBTHRACYP2C9UGT1A1ABCG2 | |
| SCHEMBL23758065 | 0.87 | THRB (0.82) | THRBTHRACYP2C9UGT1A1ABCG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250206725-A1 | MODULATORS OF THR-BETA AND METHODS OF USE THEREOF | ALIGOS THERAPEUTICS, INC. (US) | 2025-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250206725-A1 | MODULATORS OF THR-BETA AND METHODS OF USE THEREOF | THRB, THRA, TTR | THRB 1/4885THRA 2/4885CYP2C9 4603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.